中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2012, Vol. 47 Issue (14) :1164-1167    DOI:
ҩ�����ٴ� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
����ҩ���г�ҩ��ѭ֤���������о�
���1�������2��������1������1��ʩ��2��Ф³2��ʷ¼��1
1. ������ѧҩѧԺҩ�¹������ٴ�ҩѧϵ������ 100191��2. �й�ҩѧ�ᣬ���� 100022��
PU Run

Download: PDF (0KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �о��ҹ�2009��桶���һ���ҩ��Ŀ¼���г�ҩ�ٴ�ѭ֤����������Ϊ�����г�ҩ���֤��ѭ֤ҩѧ���۷����춨���������� ͨ���г�ҩѭ֤������𻮷֣�����13���г�ҩѭ֤���׷ֲ��ṹ�����Ƽ������жȺ�ʱ��仯�ص㣬���ҩƷע�����취��̽���г�ҩѭ֤���׵IJ��졣��� �����г�ҩѭ֤���׵���������������ϸߣ������������ӽϿ죬���Ƽ����ļ��жȽϸߣ���һ�����г�ҩѭ֤���׵�ǰ���������;�����ܱ����ϸߣ����Ƽ������жȽϷ�ɢ������ �г�ҩ���Է�Ϊ���࣬�ִ��г�ҩ�ɲ��ְ��Բ�Ϊ�����ѭ֤���۷������ۣ���ͳ�г�ҩ��ѭ֤���ײ������Բ�Ϊ�����ѭ֤���۷������ۡ�Ϊ�����г�ҩ���ص㣬���뽨������ҽ��֤Ϊ�����ѭ֤���۷�����
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
���
�����
������
����
ʩ��
Ф³
ʷ¼��*
�ؼ����� ����ҩ��    �г�ҩ    ѭ֤���׷���     
Abstract�� OBJECTIVE To examine the characteristics of the evidence-based clinical literatures regarding the Chinese patent medicines on the National Essential Medicine List of China (2009 Edition) so as to lay a foundation for the establishment of an evidence-based pharmaceutical review system for the Chinese patent medicines oriented at treating TCM-syndromes. METHODS The evidence-based literatures on Chinese patent medicines were categorized�� and their characteristics were analyzed concerning the distribution of the literatures according to the five levels of evidence�� the concentration of the diseases under treatment�� and chronological changes; in accordance with the Drug Registration Regulation�� the differences among these literatures were explored. RESULTS With regard to the literatures on some Chinese patent medicines�� there were a large proportion of randomized controlled trials (RCTs)�� with a rapid increase in the number of the literatures in recent years and a clear focus on certain diseases. By contrast�� some other Chinese patent medicines had a high proportion of before-after studies and empirical introductions as well as a low concentration of diseases under treatment. CONCLUSION The Chinese patent medicines can be divided into two categories�� namely�� the modern branch and the traditional branch. While the disease-oriented evidence-based review system can be applied to the evaluation of the literatures on some patent medicines in the modern branch�� it does not fit the traditional branch. Therefore�� in order to reflect the characteristics of the Chinese patent medicines�� a TCM-syndrome-oriented evidence-based review system has to be established.
Keywords�� essential medicines,   Chinese patent medicine,   categorization of the evidence-based literature     
�ո�����: 2011-12-29;
��������:

���ҿƼ�֧�żƻ��ص���Ŀ��2009BAI76B03��

���߼��: ����У���ʿ �о������ٴ�ҩѧ ��ͨѶ���ߣ�ʷ¼�ģ��У����ڣ���ʿ����ʦ �о�����ҩ�¹��� Tel����010��82805019 E-mail��shilu@bjmu.edu.cn
���ñ���:   
���, �����, �����۵� .����ҩ���г�ҩ��ѭ֤���������о�[J]  �й�ҩѧ��־, 2012,V47(14): 1164-1167
PU Run, GENG Xiang-Nan, XIN Xiao-Xiong etc .Research into Evidence-based Literatures on the Chinese Patent Medicines on the National Essential Medicine List[J]  Chinese Pharmaceutical Journal, 2012,V47(14): 1164-1167
��
[1] WANG J W. Evidence-based medicine in China[J]. Lancet�� 2010�� 375(9714)�� 532-533.
[2] NOVIASKY J A. Evidence-based pharmacy versus opinion on generic product selection of warfarin[J]. Am J Health-Syst Pharm�� 1999�� 56(1)��2246-2247.
[3] TANG J B. Information on evidence-based medicine and pharmacy. [J]. Chin Pharm J (�й�ҩѧ��־)�� 1998��33(10)�� 624-625.
[4] em>National Essential Medicine List for Primary Care Section�����һ���ҩ��Ŀ¼��[M].Beijing�� China Legal Publishing House�� 2009��19-25.
[5] National Health and Medical Research Council. How to Use the Evidence Assessment and Application of Scientific Evidence[M]. Canberra�� Commonwealth of Australia�� 2000.
[1] ���� ���� ����� ������ ���� ����.UPLC-MS/MS�ⶨ��ѹ���г�ҩ������Ʒ��30�ֻ�ѧҩ[J]. �й�ҩѧ��־, 2012,47(2): 141-145
[2] ��򣬻�־»*.���һ���ҩ���������Ż�����ȡ���Ч��ij���̽��[J]. �й�ҩѧ��־, 2012,47(13): 1094-1096
[3] �÷;ͯ��.ѭ֤ҩѧ����Ժ�����г�ҩע��Һ�е�Ӧ��[J]. �й�ҩѧ��־, 2012,47(11): 927-927
[4] ������ ��Ծƽ ������ �½� ����.ʵʩ����ҩ���ƶȶ��翵�������Ƽ���ҩ��Ӱ�����[J]. �й�ҩѧ��־, 2011,46(22): 1768-1770
[5] ��ΰ ¦���� ��� ����.��WHO��ͯ����ҩ���׼�嵥�����ҹ���ҽ��Ŀ¼����ͯ��ҩ�ĶԱȷ��������ҹ�����ʾ[J]. �й�ҩѧ��־, 2011,46(21): 1693-1696
[6] ����� ���� Ф³ ʷ¼�� .�ҹ�����ҩ�ᆳ��������������̽[J]. �й�ҩѧ��־, 2011,46(12): 963-965
[7] ë����.��վ2009����һ���ҩ��ʹ���������[J]. �й�ҩѧ��־, 2010,45(6): 479-481
[8] ����Ⱥ ���� ����.2010��桶�й�ҩ�䡷�г�ҩ��׼�ſ����ص�[J]. �й�ҩѧ��־, 2010,45(17): 1284-1286
[9] ������ ����.�г�ҩ���ο�����������Բ�[J]. �й�ҩѧ��־, 2010,45(10): 721-723
[10] ������ ;��� ;���� . ������ü������г�ҩ�����о�[J]. �й�ҩѧ��־, 2009,44(24): 1946-1947
[11] ������;ʷ¼�� .�����ҹ����һ���ҩ�����ߵ��о�[J]. �й�ҩѧ��־, 2009,44(02): 158-160
[12] ������;����;�⾧;��鳬;����Ƽ.����ҩ���ƶ�������ʵ��[J]. �й�ҩѧ��־, 2009,44(01): 1-2
[13] ����;֣����;���·�.�����г�ҩ���������������ҩ�ɷֵļ��[J]. �й�ҩѧ��־, 2006,41(12): 945-947
[14] ����ǿ ��� ����� �η���.�ٴ���������Ӧ��ҩ�����ķ�������ҩ����Ԥ��[J]. �й�ҩѧ��־, 2000,35(12): 858-860
[15] ����΢.��������һ���ҩ��ʹ�����������������[J]. �й�ҩѧ��־, 1998,33(03): 177-178
Copyright 2010 by �й�ҩѧ��־